Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 392-395

  Teixeira, Lisete R ^a   Vargas, Francisco S ^a   Acencio, Milena M P ^a   Ribeiro, Sabrina C ^a   Sales, Roberta K B ^a   Antonangelo, Leila ^a   Marchi, Evaldo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti VEGF antibody; Bevacizumab; Malignant pleural effusion; Pleurodesis; Silver nitrate; Talc

Indexed keywords

BEVACIZUMAB; COLLAGEN FIBER; SILVER NITRATE; TALC; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PARAMETERS; CONTROLLED STUDY; NEW ZEALAND; NONHUMAN; PLEURA; PLEURODESIS; PNEUMONIA; PRIORITY JOURNAL; THICKNESS; TISSUE ADHESION; VASCULAR DENSITY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL ADHESION; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAVENOUS; NEOVASCULARIZATION, PHYSIOLOGIC; PLEURA; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; RABBITS; SILVER NITRATE; TALC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80755190048     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.015     Document Type: Article

References (19)

1. Light R.W., Vargas F.S. Pleural sclerosis for the treatment of pneumothorax and pleural effusion. Lung 1997, 175:213-223.
2. Marchi E., Vargas F.S., Teixeira L.R., Acencio M.M.P., Antonangelo L., Light R.W. Intrapleural low-dose silver nitrate elicits more pleural inflammation and less systemic inflammation than low-dose talc. Chest 2005, 128:1798-1804.
3. Marchi E., Vargas F.S., Acencio M.M., Antonangelo L., Teixeira L.R., Genofre E.H., et al. Talc and silver nitrate induce systemic inflammatory effects in the acute phase of experimental pleurodesis in rabbits. Chest 2004, 125:2268-2277.
4. Breier G., Albrecht U., Sterrer S., Risau W. Expression of vascular endothelial growth factor during angiogenesis and endothelial cell differentiation. Development 1992, 114:521-532.
5. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77:527-543.
6. Cheng D.S., Rodriguez R.M., Perkett E.A., Rogers J., Bienvenu G., Lappalainen U., et al. Vascular endothelial growth factor in pleural fluid. Chest 1999, 116:760-765.
7. Grove C.S., Lee Y.C.G. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002, 8:294-301.
8. Ribeiro S.C.C., Vargas F.S., Antonangelo L., Marchi E., Genofre E.H., Acencio M.M., et al. Monoclonal anti-vascular endothelial growth factor reduces fluid volume in experimental model of inflammatory pleural effusion. Respiration 2009, 14:1188-1193.
9. Guo Y.B., Kalomenidis I., Hawthorne M., Parman K.S., Lane K.B., Light R.W. Pleurodesis is inhibited by vascular endothelial growth factor antibody. Chest 2005, 128:1790-1797.
10. Guo Y.B., Xie C.M., Light R.W. Effect of anti-vascular endothelial growth factor on pleurodesis induced by transforming growth factor-beta or doxycicline in rabbits. Zhonghua Jie He He Hu Xi Za Zhi 2006, 29:39-43.
11. Reck M., Crino L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 2009, 63:1-9.
12. Teixeira L.R., Wu W., Cheng D.S., Light R.W. The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. Chest 2002, 121:216-219.
13. Teixeira L.R., Vargas F.S., Acencio M.M.P., Bumlai R.U.M., Antonangelo L., Marchi E. Experimental pleurodesis induced by antibiotics (macrolides or quinolones). Clinics 2006, 61:559-564.
14. Antonangelo L., Vargas F.S., Teixeira L.R., Acencio M.M., Vaz M.A., Filho M.T., et al. Pleurodesis induced by talc or silver nitrate: evaluation of collagen and elastic fibers in pleural remodeling. Lung 2006, 184:105-111.
15. Detmar M., Brown L.F., Schön M.P., Elicker B.M., Velasco P., Richard L., et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998, 111:1-6.
16. Lee Y.C.G., Devore R., Novotny W., Light R.W. The effects of recombinant human monoclonal antibodies against vascular endothelial growth factor on malignant pleural effusions in patients with non-small cell lung carcinoma [abstract]. Chest 2001, 120(Suppl.):193S.
17. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235:442-447.
18. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of Bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
19. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.